DK1948798T3 - Anti-alpha2-integrin-antistoffer og anvendelser deraf - Google Patents

Anti-alpha2-integrin-antistoffer og anvendelser deraf Download PDF

Info

Publication number
DK1948798T3
DK1948798T3 DK06804739.8T DK06804739T DK1948798T3 DK 1948798 T3 DK1948798 T3 DK 1948798T3 DK 06804739 T DK06804739 T DK 06804739T DK 1948798 T3 DK1948798 T3 DK 1948798T3
Authority
DK
Denmark
Prior art keywords
integrin
antibody
seq
amino acid
acid sequence
Prior art date
Application number
DK06804739.8T
Other languages
English (en)
Inventor
Elias Lazarides
Catherine Woods
Mark A Bernard
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Application granted granted Critical
Publication of DK1948798T3 publication Critical patent/DK1948798T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)

Claims (42)

1. Humaniseret anti-a2-integrinantistof, omfattende: (i) en variabel region med tung kæde, omfattende aminosyresekvensen af (a) HCDR1 (GFSLTNYGIH, SEQ ID NO:1), (b) HCDR2 (VIWARG- FTNYNSALMS, SEQ ID NO:2) og (c) HCDR3 (ANDGVYYAMDY, SEQ ID NO:3); og (ii) en variabel region med let kæde, omfattende aminosyresekvensen af (a) en LCDR1, der er valgt blandt SANSSVNYIH (SEQ ID NO:4) eller SAQSSVNYIH (SEQ ID NO:112), (b) LCDR2 (DTSKLAS; SEQ ID NO:5) og (c) LCDR3 (QQWTTNPLT, SEQ ID NO:6).
2. Humaniseret anti-a2-integrinantistof ifølge krav 1, hvor (a) den variable region med tung kæde omfatter aminosyresekvensen med SEQ ID NO:185, (b) den variable region med let kæde omfatter aminosyresekvensen med SEQ ID NO:186 eller (c) både (a) og (b).
3. Humaniseret anti-a2-integrinantistof ifølge krav 1, hvor (i) den variable region med tung kæde omfatter aminosyresekvensen med SEQ ID NO: 185, hvor (a) position 71 er Lys, (b) position 73 er Asn, (c) position 78 er Val eller (d) en hvilken som helst kombination af (a)-(c); (ii) den variable region med let kæde omfatter aminosyresekvensen med SEQ ID NO:186, hvor (a) position 2 er Phe, (b) position 45 er Lys, (c) position 48 er Tyr eller (d) en hvilken som helst kombination af (a)-(c); eller (iii) både (i) og (ii).
4. Humaniseret anti-a2-integrinantistof ifølge krav 1, hvor (a) den variable region med tung kæde omfatter en aminosyresekvens, der er valgt blandt SEQ ID NO:70-79 og SEQ ID NO:109-111; (b) den variable region med let kæde omfatter en aminosyresekvens, der er valgt blandt SEQ ID NO:41, SEQ ID NO:80-92 og SEQ ID NO:108; eller (c) både (a) og (b).
5. Humaniseret anti-a2-integrinantistof ifølge krav 1, hvor den variable region med tung kæde endvidere omfatter en FW4-region, omfattende aminosyre-sekvensen WGQGTLVTVSS (SEQ ID NO:13).
6. Humaniseret anti-a2-integrinantistof ifølge krav 1, hvor den variable region med let kæde endvidere omfatter en FW4-region, omfattende aminosyrese-kvensen FGQGTKVEIK (SEQ ID NO:38).
7. Humaniseret anti-a2-integrinantistof ifølge krav 1, hvor antistoffet genkender l-domænet af human-a2-integrin.
8. Humaniseret anti-a2-integrinantistof ifølge krav 1, hvor antistoffet binder α2β1 -integrin.
9. Humaniseret anti-a2-integrinantistof ifølge krav 1, hvor antistoffet binder en epitop af a2-integrin, hvilken epitop omfatter: (a) en Lys-rest, der svarer til position 192 af a2-integrin-aminosyresekvensen i SEQ ID NO:8 eller position 40 af a2-integrin-l-domæne- aminosyresekvensen i SEQ ID NO:11; (b) en Asn-rest, der svarer til position 225 af a2-integrin-aminosyresekvensen i SEQ ID NO:8 eller position 73 af a2-integrin-l-domæne- aminosyresekvensen i SEQ ID NO:11; (c) en Gin-rest, der svarer til position 241 af a2-integrin-aminosyresekvensen i SEQ ID NO:8 eller position 89 af a2-integrin-l-domæne- aminosyresekvensen i SEQ ID NO: 11; (d) en Tyr-rest, der svarer til position 245 af a2-integrin-aminosyresekvensen i SEQ ID NO:8 eller position 93 af a2-integrin-l-domæne- aminosyresekvensen i SEQ ID NO:11; (e) en Arg-rest, der svarer til position 317 af a2-integrin-aminosyresekvensen i SEQ ID NO:8 eller position 165 af a2-integrin-l-domæne-aminosyresekvensen i SEQ ID NO: 11; (f) en Asn-rest, der svarer til position 318 af a2-integrin-aminosyresekvensen i SEQ ID NO:8 eller position 166 af a2-integrin-l-domæne-aminosyresekvensen i SEQ ID NO: 11; eller (g) en hvilken som helst kombination af (a) til (f).
10. Humaniseret anti-a2-integrinantistof, hvor antistoffet binder en epitop af a2-integrin, hvilken epitop omfatter: (a) en Lys-rest, der svarer til position 192 af a2-integrin-aminosyresekvensen i SEQ ID NO:8 eller position 40 af a2-integrin-l-domæne- aminosyresekvensen i SEQ ID NO: 11; (b) en Asn-rest, der svarer til position 225 af a2-integrin-aminosyresekvensen i SEQ ID NO:8 eller position 73 af a2-integrin-l-domæne- aminosyresekvensen i SEQ ID NO: 11; (c) en Gin-rest, der svarer til position 241 af a2-integrin-aminosyresekvensen i SEQ ID NO:8 eller position 89 af a2-integrin-l-domæne- aminosyresekvensen i SEQ ID NO: 11; (d) en Tyr-rest, der svarer til position 245 af a2-integrin-aminosyresekvensen i SEQ ID NO:8 eller position 93 af a2-integrin-l-domæne- aminosyresekvensen i SEQ ID NO: 11; (e) en Arg-rest, der svarer til position 317 af a2-integrin-aminosyresekvensen i SEQ ID NO:8 eller 165 af a2-integrin-l-domæne-aminosyresekvensen i SEQ ID NO:11; og (f) en Asn-rest, der svarer til position 318 af a2-integrin-aminosyresekvensen i SEQ ID NO:8 eller position 166 af a2-integrin-l-domæne-aminosyresekvensen i SEQ ID NO: 11.
11. Humaniseret anti-a2-integrinantistof ifølge krav 1, der er et antistof i fuld længde.
12. Humaniseret anti-a2-integrinantistof ifølge krav 1, der er et antistoffragment.
13. Humaniseret anti-a2-integrinantistof ifølge krav 1, der er bundet til en de-tekterbar markering.
14. Humaniseret anti-a2-integrinantistof ifølge krav 1, der er immobiliseret på en fast fase.
15. Humaniseret anti-a2-integrinantistof ifølge krav 1, hvor antistoffet inhibe-rer binding af a2- eller α2β1 -integrin til en α2β1 -integrinligand.
16. Humaniseret anti-a2-integrinantistof ifølge krav 15, hvor α2β1-integrinliganden er valgt blandt kollagen, laminin, Echovirus-1, decorin, E-cadherin, matrix-metalloproteinase-l (MMP-I), endorepellin, kollektin og Clq-komplement-protein.
17. Fremgangsmåde til bestemmelse af, om en prøve indeholder a2-integrin, α2β1 -integrin eller begge, omfattende at bringe prøven i kontakt med den humaniserede anti-a2-integrinantistof ifølge krav 1, og bestemmelse af, om antistoffet binder til prøven, hvor bindingen er en indikation på, at prøven indeholder a2-integrin, α2β1 -integrin eller begge.
18. Kit omfattende det humaniserede anti-a2-integrinantistof ifølge krav 1 og anvisninger til anvendelse deraf til detektion af a2- eller α2β1 -integrinprotein.
19. Isoleret nukleinsyre, der koder for et humaniseret anti-a2pi-integrinantistof ifølge krav 1.
20. Vektor omfattende nukleinsyren ifølge krav 19.
21. Værtscelle omfattende: (a) nukleinsyren ifølge krav 19; (b) vektoren ifølge krav 20; eller (c) en hvilken som helst kombination af (a) og (b).
22. Fremgangsmåde til fremstilling af en humaniseret anti-a2-integrinantistof, omfattende at dyrke værtscellen ifølge krav 21 under betingelser, der muliggør ekspression af antistoffet.
23. Fremgangsmåde ifølge krav 22, endvidere omfattende at genvinde det humaniserede anti-a2-integrinantistof fra værtscellen.
24. Fremgangsmåde ifølge krav 23, hvor det humaniserede anti-a2pi-integrinantistof genvindes fra værtscelledyrkningsmediet.
25. Screeningfremgangsmåde, omfattende: (a) at detektere binding af a2- eller α2β1 -integrin til et antistof, omfattende VL-regionen med SEQ ID NO:19 og VH-regionen med SEQ ID NO:21 under nærvær eller fravær af et testantistof; og (b) at vælge testantistoffet, hvis nærvær deraf korrelerer med reduceret binding af a2- eller a2pi-integrinet til antistoffet, omfattende VL-regionen med SEQ ID NO:19 og VH-regionen med SEQ ID NO:21.
26. Fremgangsmåde ifølge krav 25, hvor a2- eller a2pi-integrinet immobilise-res på en fast bærer.
27. Screeningfremgangsmåde, omfattende: (a) at detektere binding af α2β1 -integrin til kollagen under nærvær af et testantistof, hvor testantistoffet er et antistof, der binder til et a2 l-domæne; (b) at detekrere binding af testantistoffet til a2 l-domænet under nærvær af Mg++-ioner; (c) at detektere binding af testantistoffet til a2 l-domænet under nærvær af Ca++-ioner; (d) at detektere binding af testantistoffet til a2 l-domænet under nærvær af kation-frie medier; og (e) at vælge testantistoffet, hvis det inhiberer bindingen af α2β1 -integrin til kollagen og binder til a2 l-domænet under nærvær af Mg++-ioner og Ca++-ioner og kation-frie medier.
28. Sammensætning omfattende det humaniserede anti-a2-integrinantistof ifølge krav 1 og en farmaceutisk acceptabel bærer.
29. Humaniseret anti-a2-integrinantistof ifølge krav 10 til anvendelse i en in v/Vo-fremgangsmåde til inhibering af leukocyt, der binder til kollagen, omfattende administration af en mængde af antistoffet til individet, der er virksom til at inhibere bindingen af leukocytterne til kollagen.
30. Fremgangsmåde til målrette et molekyle, en sammensætning eller et kompleks til et sted, kendetegnet ved nærværelse af en α2β1 -integrinligand, hvilken fremgangsmåde omfatter at fastgøre eller binde molekylet, sammensætningen eller komplekset til det humaniserede anti-a2-integrinantistof ifølge krav 1.
31. Humaniseret anti-a2-integrinantistof ifølge et af kravene 1-16 til anvendelse som et lægemiddel.
32. Humaniseret anti-a2-integrinantistof ifølge et af kravene 1-16 eller sammensætning ifølge krav 28 til anvendelse i en fremgangsmåde til behandling af en a2pi-integrin-relateret lidelse, der er valgt blandt inflammatorisk sygdom, autoimmun sygdom, en sygdom, der er forbundet med unormal angio-genese eller angiogenese, der er højere end normalt, inflammatorisk tarmsygdom, Crohns sygdom, colitis ulcerosa, reaktioner ved transplantation, optisk neuritis, rygmarvsbeskadigelse, reumatoid artritis, systemisk lupus erythematosus (SLE), diabetes mellitus, multipel sklerose, Reynauds syndrom, eksperimentel autoimmun encephalomyelitis, Sjøgrens syndrom, scleroderma, type 1-diabetes, diabetisk retinopati, aldersrelateret makulær degeneration, kardiovaskulær sygdom, psoriasis, cancer samt infektioner, der bevirker en inflammatorisk reaktion.
33. Anvendelse af humaniseret anti-a2-integrinantistof ifølge et af kravene 1-16 til fremstilling af et lægemiddel til behandling af en a2pi-integrin-relateret lidelse, der er valgt blandt inflammatorisk sygdom, autoimmun sygdom, en sygdom, der er forbundet med unormal angiogenese eller angiogenese, der er højere end normalt, inflammatorisk tarmsygdom, Crohns sygdom, colitis ulcerosa, reaktioner ved transplantation, optisk neuritis, rygmarvsbeskadigelse, reumatoid artritis, systemisk lupus erythematosus (SLE), diabetes melli-tus, multipel sklerose, Reynauds syndrom, eksperimentel autoimmun encephalomyelitis, Sjøgrens syndrom, scleroderma, type 1-diabetes, diabetisk retinopati, aldersrelateret makulær degeneration, kardiovaskulær sygdom, psoriasis, cancer samt infektioner, der bevirker en inflammatorisk reaktion.
34. Anvendelse ifølge krav 33, hvor den a2pi-integrin-relaterede lidelse er valgt blandt multipel sklerose, reumatoid artritis, optisk neuritis og rygmarvsbeskadigelse.
35. Anvendelse ifølge krav 33, hvor den a2pi-integrin-relaterede lidelse ikke er forbundet med (a) blodpladeaktivering, (b) blodpladeaggregation, (c) en reduktion af antallet af cirkulerende blodplader, (d) blødningskomplikationer eller (e) en hvilken som helst kombination af (a) til (d).
36. Anvendelse ifølge krav 33, hvor anti-a2-integrinantistoffet omfatter en tung kæde, omfattende SEQ ID NO: 174 eller SEQ ID NO:176 og en let kæde, omfattende SEQ ID NO: 178.
37. Anvendelse ifølge krav 33, hvor anti-a2-integrinantistoffet kompetitivt in-hiberer bindingen af et antistof, omfattende VL-regionen med SEQ ID NO: 19 og VH-regionen med SEQ ID NO:21 til humant α2β1 -integrin eller l-domænet deraf.
38. Anvendelse ifølge krav 34, hvor nævnte multipel sklerose er kendetegnet ved tilbagefald.
39. Anvendelse ifølge krav 33, hvor anti-a2-integrinantistoffet inhiberer bindingen af α2β1 -integrin til kollagen og ikke er en mimetisk ligand.
40. Sammensætning til anvendelse ved behandling af en α2β1 -integrin-relateret lidelse, der er valgt blandt inflammatorisk sygdom, autoimmun sygdom, en sygdom, der er forbundet med unormal angiogenese eller angioge-nese, der er højere end normalt, inflammatorisk tarmsygdom, Crohns sygdom, colitis ulcerosa, reaktioner ved transplantation, optisk neuritis, rygmarvsbeskadigelse, reumatoid artritis, systemisk lupus erythematosus (SLE), diabetes mellitus, multipel sklerose, Reynauds syndrom, eksperimentel autoimmun encephalomyelitis, Sjøgrens syndrom, scleroderma, type 1-diabetes, diabetisk retinopati, aldersrelateret makulær degeneration, kardiovaskulær sygdom, psoriasis, cancer samt infektioner, der bevirker en inflammatorisk reaktion, hvor sammensætningen omfatter det humaniserede anti-a2-integrinantistof ifølge et af kravene 1-16 og en farmaceutisk acceptabel bærer eller fortyndingsmiddel.
41. Sammensætning til anvendelse ved behandling ifølge krav 40, hvor den c^1-integrin-relaterede lidelse er valgt blandt multipel sklerose, reumatoid artritis, optisk neuritis og rygmarvsbeskadigelse.
42. Pakke, der omfatter det humaniserede anti-a2-integrinantistof ifølge et af kravene 1-16 eller sammensætningen ifølge et af kravene 40 eller 41 sammen med anvisninger til behandling af en a2pi-integrin-relateret lidelse.
DK06804739.8T 2005-11-18 2006-11-17 Anti-alpha2-integrin-antistoffer og anvendelser deraf DK1948798T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73830305P 2005-11-18 2005-11-18
PCT/CA2006/001876 WO2007056858A1 (en) 2005-11-18 2006-11-17 Anti-alpha2 integrin antibodies and their uses

Publications (1)

Publication Number Publication Date
DK1948798T3 true DK1948798T3 (da) 2015-07-06

Family

ID=38048251

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06804739.8T DK1948798T3 (da) 2005-11-18 2006-11-17 Anti-alpha2-integrin-antistoffer og anvendelser deraf

Country Status (23)

Country Link
US (3) US7807794B2 (da)
EP (2) EP1948798B1 (da)
JP (1) JP5184367B2 (da)
KR (1) KR101442266B1 (da)
CN (1) CN101360826B (da)
AP (1) AP2809A (da)
AU (1) AU2006315037C1 (da)
CA (1) CA2629715C (da)
DK (1) DK1948798T3 (da)
EA (1) EA016245B9 (da)
ES (1) ES2541302T3 (da)
HK (1) HK1121186A1 (da)
HR (1) HRP20150691T1 (da)
IL (1) IL191264A (da)
MY (1) MY147669A (da)
NO (1) NO20082454L (da)
NZ (1) NZ568272A (da)
PL (1) PL1948798T3 (da)
PT (1) PT1948798E (da)
RS (1) RS54111B1 (da)
SI (1) SI1948798T1 (da)
WO (1) WO2007056858A1 (da)
ZA (1) ZA200804148B (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2541302T3 (es) * 2005-11-18 2015-07-17 Glenmark Pharmaceuticals S.A. Anticuerpos anti-integrina alfa2 y sus usos
US20080267978A1 (en) * 2006-08-28 2008-10-30 Mary Zutter Anti-angiogenic targets for cancer therapy
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AR072001A1 (es) 2008-06-03 2010-07-28 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
KR101054725B1 (ko) 2008-07-31 2011-08-05 재단법인서울대학교산학협력재단 세포외기질 성분을 함유하는 노화조절용 조성물 및 이를이용한 노화세포의 노화조절방법
NZ592436A (en) * 2008-11-06 2012-10-26 Glenmark Pharmaceuticals Sa Treatment with anti-alpha2 integrin antibodies
KR101667227B1 (ko) * 2009-03-10 2016-10-18 가부시키가이샤 진 테크노 사이언스 인간화된 ｋ33ｎ 단일 클론 항체의 제조, 발현 및 해석
US9358273B2 (en) 2010-01-06 2016-06-07 The Texas A&M University System Use of perlecan domain V in treating amyloidogenic disease
CA3027824A1 (en) * 2010-02-23 2011-09-01 Sanofi Anti-alpha2 integrin antibodies and their uses
CN102190728B (zh) * 2010-03-17 2014-07-02 永卓博济(上海)生物医药技术有限公司 一种人源化抗cd20单克隆抗体
WO2011119732A2 (en) * 2010-03-24 2011-09-29 Stc.Unm Method for integrin ligand discovery
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AR082461A1 (es) 2010-08-03 2012-12-12 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TWI560199B (en) * 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
US9170138B2 (en) * 2010-10-01 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Enhanced microfluidic electromagnetic measurements
DK2663579T3 (da) 2011-01-14 2017-07-31 Univ California Terapeutiske antistoffer mod ror-1-protein og fremgangsmåder til anvendelse deraf
CA2812739A1 (en) 2011-03-25 2012-10-04 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
EP2710037B1 (en) * 2011-05-19 2019-07-31 The Regents of The University of Michigan Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
WO2014003137A1 (ja) * 2012-06-27 2014-01-03 旭化成メディカル株式会社 高アフィニティー抗体、及びその製造方法
EP3060580B1 (en) * 2013-10-21 2021-03-31 Centre For Drug Research And Development Anti-podocalyxin antibodies and methods of using the same
CA3000242A1 (en) 2015-10-01 2017-04-06 The Centre For Drug Research And Development Anti-podocalyxin antibodies and methods of using the same
KR20210040378A (ko) * 2018-07-03 2021-04-13 카탈렌트 파마 솔루션즈, 엘엘씨 데코린을 포함하는 다기능 단백질 분자 및 이의 용도
CN110007628B (zh) * 2019-04-10 2022-02-01 深圳市华星光电半导体显示技术有限公司 Goa电路及显示面板
US20220133913A1 (en) * 2019-07-24 2022-05-05 Korea Basic Science Institute SINGLE DOMAIN ANTIBODY TARGETING aVB3 INTEGRIN
KR20220079857A (ko) * 2019-09-13 2022-06-14 루트거스, 더 스테이트 유니버시티 오브 뉴 저지 Aav-상용성 라미닌-링커 중합 단백질
CN111088227A (zh) * 2019-12-31 2020-05-01 广州航华生物医药科技有限公司 一种细胞分离培养液和t细胞分离培养的方法
CN114931665A (zh) * 2021-12-14 2022-08-23 广州医科大学 六型胶原α2亚基在神经修复产品中的应用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
ATE68013T1 (de) 1985-07-05 1991-10-15 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5306620A (en) 1987-07-08 1994-04-26 The Scripps Research Institute Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
DE3852823T2 (de) 1987-09-11 1995-05-24 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
JP2917998B2 (ja) 1988-02-05 1999-07-12 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 修飾された肝細胞およびその用途
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5196511A (en) * 1989-12-01 1993-03-23 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5262520A (en) * 1989-12-01 1993-11-16 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
AU656544B2 (en) 1990-10-31 1995-02-09 Brigham And Women's Hospital Genetic modification of endothelial cells
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
US6291196B1 (en) * 1992-01-31 2001-09-18 Research Corporation Technologies, Inc. Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
DK0802800T3 (da) 1993-08-12 2002-10-07 Neurotech Sa Biokompatible immunoisolatoriske kapsler indeholdende genetisk ændrede celler for levering af biologisk aktive molekyler
US5523209A (en) * 1994-03-14 1996-06-04 The Scripps Research Institute Methods for identifying inhibitors of integrin activation
ATE195428T1 (de) * 1994-04-26 2000-09-15 Kanebo Ltd Arznei für rheumatoide arthritis
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997004133A1 (en) 1995-07-21 1997-02-06 Regents Of The University Of Minnesota Analysis of alpha integrins for the diagnosis of diabetic nephropathy
US5858709A (en) 1996-10-15 1999-01-12 Smithkline Beecham P.L.C. Fibronectin binding protein B compounds
US6025155A (en) 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20020160970A1 (en) 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
AU5595198A (en) 1996-11-21 1998-06-10 Cor Therapeutics, Inc. Modulation of interactions between myosin and integrins
US5932421A (en) 1996-12-06 1999-08-03 The Scripps Research Institute Methods and cell lines for identification of regulators of integrin activation
EP0879602A1 (en) 1997-05-21 1998-11-25 Rijksuniversiteit te Leiden A method to increase the survival of transplanted cells
US6596276B1 (en) 1997-09-30 2003-07-22 Beth Israel Deaconess Medical Center Method for inhibiting tumor angiogenesis in a living subject
EP1121151B1 (en) 1998-10-07 2006-12-13 Lennart Lindbom Anti-inflammatory alpha2, beta1 integrin-related substances or antibodies
US6849425B1 (en) * 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
CA2453403C (en) 2001-07-09 2013-10-08 Elan Pharmaceuticals, Inc. Methods of inhibiting amyloid toxicity
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
DE10354806A1 (de) * 2003-11-21 2005-06-02 Boehringer Ingelheim Microparts Gmbh Probenträger
WO2006022682A2 (en) * 2004-08-06 2006-03-02 Applera Corporation Method and compositions for treating diseases targeting cd49b
EA200701211A1 (ru) * 2004-12-31 2007-12-28 Дженентек, Инк. Полипептиды, которые связываются с br3, и их применение
CA2619654A1 (en) 2005-08-24 2007-03-01 Cell Matrix Combination therapies for inhibiting integrin-extracellular matrix interactions
ES2541302T3 (es) * 2005-11-18 2015-07-17 Glenmark Pharmaceuticals S.A. Anticuerpos anti-integrina alfa2 y sus usos
US20080267978A1 (en) 2006-08-28 2008-10-30 Mary Zutter Anti-angiogenic targets for cancer therapy
FI20075258A0 (fi) * 2007-04-17 2007-04-17 Biotie Therapies Corp Menetelmä integriiniinhibiittorirespondereiden seulomiseksi

Also Published As

Publication number Publication date
CN101360826B (zh) 2014-04-30
US8759009B2 (en) 2014-06-24
US20110135635A1 (en) 2011-06-09
MY147669A (en) 2012-12-31
EA016245B9 (ru) 2013-04-30
US20140341892A1 (en) 2014-11-20
PL1948798T3 (pl) 2015-12-31
AU2006315037A1 (en) 2007-05-24
EP1948798A1 (en) 2008-07-30
PT1948798E (pt) 2015-08-05
KR101442266B1 (ko) 2014-11-04
CA2629715A1 (en) 2007-05-24
WO2007056858A1 (en) 2007-05-24
CA2629715C (en) 2016-05-03
AP2008004471A0 (en) 2008-06-30
HK1121186A1 (en) 2009-04-17
HRP20150691T1 (hr) 2015-11-06
AU2006315037B2 (en) 2012-09-06
NO20082454L (no) 2008-07-17
EP1948798A4 (en) 2010-02-24
JP2009516506A (ja) 2009-04-23
KR20080074184A (ko) 2008-08-12
EP1948798B1 (en) 2015-04-01
JP5184367B2 (ja) 2013-04-17
CN101360826A (zh) 2009-02-04
NZ568272A (en) 2012-02-24
AP2809A (en) 2013-12-31
ES2541302T3 (es) 2015-07-17
RS54111B1 (en) 2015-12-31
EA200801314A1 (ru) 2008-10-30
AU2006315037C1 (en) 2013-05-02
ZA200804148B (en) 2009-12-30
US7807794B2 (en) 2010-10-05
SI1948798T1 (sl) 2015-09-30
IL191264A (en) 2016-04-21
EP3023497A1 (en) 2016-05-25
US20070128190A1 (en) 2007-06-07
EA016245B1 (ru) 2012-03-30

Similar Documents

Publication Publication Date Title
DK1948798T3 (da) Anti-alpha2-integrin-antistoffer og anvendelser deraf
KR102100388B1 (ko) Cd47 항체 및 그 사용 방법
KR102276974B1 (ko) 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법
RU2588668C2 (ru) ПЕПТИД ИЛИ ПЕПТИДНЫЙ КОМПЛЕКС, СВЯЗЫВАЮЩИЙСЯ С альфа2-ИНТЕГРИНОМ, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ УКАЗАННОГО ВЕЩЕСТВА
US20240076365A1 (en) Gremlin-1 crystal structure and inhibitory antibody
EA031948B1 (ru) Антитело к il-36r или его антигенсвязывающий фрагмент, выделенный полинуклеотид, клетка-хозяин и способ получения этого антитела или его фрагмента, содержащая их фармацевтическая композиция и применение антитела или его фрагмента и композиции
AU2009312532B2 (en) Treatment with anti-alpha2 integrin antibodies
US11542329B2 (en) Antibodies targeting Glycoprotein VI
MX2008006459A (en) Anti-alpha2 integrin antibodies and their uses
BRPI0620469A2 (pt) anticorpo humanizado anti-integrina alfa2, método para determinar se uma amostra contém a integrina alfa2, kit, ácido nucléico isolado, vetor, célula hospedeira, processo para produção de um anticorpo humanizado anti-integrina alfa2, método de triagem, composição, método para o tratamento de distúrbios associados com a integrina alfa2beta1 em pacientes, método para a inibição da ligação de leucócitos ao colágeno, método de direcionar uma molécula, uso de um anticorpo humanizado anti-integrina alfa2, embalagem e epitopo da integrina alfa2 que liga um anticorpo anti-integrina alfa 2